Jupiter licenses ALA-002 from PharmAla

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) announced on July 21, 2026, that it has entered into a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002, a patented non-racemic MDMA formulation designated as a Novel Chemical Entity by the FDA. The transaction is valued at up to $100 million, including milestone payments, and expands Jupiter from a single-program company into a dual clinical-stage CNS developer. The upfront payment is $3.3 million ($1.5 million cash and $1.8 million in Jupiter common stock). Additional milestones include $3.3 million upon Phase 3 first patient in, $20 million upon U.S. NDA approval, and commercial milestones totaling $73.3 million based on cumulative net sales. Jupiter will also pay a 3% royalty on net sales after the third commercialization milestone. PharmAla will continue to manufacture ALA-002 for Jupiter. The agreement leverages a recent Executive Order signed by President Donald Trump on April 18, 2026, titled 'Accelerating Medical Treatments for Serious Mental Illness,' which directs the FDA and DEA to expand access to investigational psychedelic therapies. ALA-002 targets the U.S. psychedelic therapeutics market, estimated at $3 billion in 2024 and projected to reach $8 billion by 2030.